Celldex Therapeutics (NASDAQ:CLDX) was downgraded by investment analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Thursday.

CLDX has been the subject of a number of other reports. Cantor Fitzgerald reiterated a “buy” rating and set a $9.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, September 26th. WBB Securities reiterated a “buy” rating and set a $10.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, December 6th. Finally, HC Wainwright reiterated a “buy” rating on shares of Celldex Therapeutics in a research report on Tuesday, November 7th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $7.05.

Shares of Celldex Therapeutics (NASDAQ CLDX) traded down $0.06 during trading on Thursday, hitting $2.80. 1,121,816 shares of the stock were exchanged, compared to its average volume of 1,066,176. Celldex Therapeutics has a 12 month low of $2.20 and a 12 month high of $3.94. The company has a market cap of $380.76, a P/E ratio of -2.77 and a beta of 2.73.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.27) by $0.07. The business had revenue of $3.90 million during the quarter, compared to analysts’ expectations of $1.30 million. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The firm’s quarterly revenue was up 77.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.29) EPS. equities research analysts forecast that Celldex Therapeutics will post -0.93 EPS for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC acquired a new position in Celldex Therapeutics during the 3rd quarter worth approximately $101,000. OxFORD Asset Management LLP acquired a new position in Celldex Therapeutics during the 3rd quarter worth approximately $122,000. Voya Investment Management LLC increased its position in Celldex Therapeutics by 17.4% during the 2nd quarter. Voya Investment Management LLC now owns 50,535 shares of the biopharmaceutical company’s stock worth $125,000 after purchasing an additional 7,499 shares in the last quarter. Pacad Investment Ltd. acquired a new position in Celldex Therapeutics in the 2nd quarter valued at approximately $150,000. Finally, BlueCrest Capital Management Ltd acquired a new position in Celldex Therapeutics in the 2nd quarter valued at approximately $158,000. Institutional investors and hedge funds own 52.46% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Celldex Therapeutics (CLDX) Stock Rating Lowered by BidaskClub” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2018/01/14/celldex-therapeutics-cldx-stock-rating-lowered-by-bidaskclub.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.